Shinabarger D L, Marotti K R, Murray R W, Lin A H, Melchior E P, Swaney S M, Dunyak D S, Demyan W F, Buysse J M
Infectious Diseases Research, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001-0199, USA.
Antimicrob Agents Chemother. 1997 Oct;41(10):2132-6. doi: 10.1128/AAC.41.10.2132.
The oxazolidinones are a new class of synthetic antibiotics with good activity against gram-positive pathogenic bacteria. Experiments with a susceptible Escherichia coli strain, UC6782, demonstrated that in vivo protein synthesis was inhibited by both eperezolid (formerly U-100592) and linezolid (formerly U-100766). Both linezolid and eperezolid were potent inhibitors of cell-free transcription-translation in E. coli, exhibiting 50% inhibitory concentrations (IC50s) of 1.8 and 2.5 microM, respectively. The ability to demonstrate inhibition of in vitro translation directed by phage MS2 RNA was greatly dependent upon the amount of RNA added to the assay. For eperezolid, 128 microg of RNA per ml produced an IC50 of 50 microM whereas a concentration of 32 microg/ml yielded an IC50 of 20 microM. Investigating lower RNA template concentrations in linezolid inhibition experiments revealed that 32 and 8 microg of MS2 phage RNA per ml produced IC50s of 24 and 15 microM, respectively. This phenomenon was shared by the translation initiation inhibitor kasugamycin but not by streptomycin. Neither oxazolidinone inhibited the formation of N-formylmethionyl-tRNA, elongation, or termination reactions of bacterial translation. The oxazolidinones appear to inhibit bacterial translation at the initiation phase of protein synthesis.
恶唑烷酮类是一类新型合成抗生素,对革兰氏阳性病原菌具有良好活性。用敏感的大肠杆菌菌株UC6782进行的实验表明,依哌唑胺(原U-100592)和利奈唑胺(原U-100766)在体内均能抑制蛋白质合成。利奈唑胺和依哌唑胺都是大肠杆菌无细胞转录-翻译的强效抑制剂,其50%抑制浓度(IC50)分别为1.8和2.5微摩尔。证明对噬菌体MS2 RNA指导的体外翻译有抑制作用的能力在很大程度上取决于测定中添加的RNA量。对于依哌唑胺,每毫升128微克RNA产生的IC50为50微摩尔,而32微克/毫升的浓度产生的IC50为20微摩尔。在利奈唑胺抑制实验中研究较低RNA模板浓度时发现,每毫升32和8微克MS2噬菌体RNA产生的IC50分别为24和15微摩尔。这种现象在翻译起始抑制剂春日霉素中也存在,但在链霉素中不存在。两种恶唑烷酮类药物均不抑制细菌翻译中N-甲酰甲硫氨酰-tRNA的形成、延伸或终止反应。恶唑烷酮类药物似乎在蛋白质合成的起始阶段抑制细菌翻译。